曲美他嗪联合瑞舒伐他汀治疗缺血性心肌病心力衰竭的疗效

The efficacy of trimetazidine combined with rosuvastatin in the treatment of heart failure and ischemic cardiomyopathy

目的分析缺血性心肌病心力衰竭患者应用曲美他嗪联合瑞舒伐他汀治疗的疗效。方法92例缺血性心肌病心力衰竭患者作为研究对象,采取电脑系统随机排序分组的方式分为对照组和观察组,每组46例。对照组采用瑞舒伐他汀治疗,观察组采用曲美他嗪联合瑞舒伐他汀治疗。比较两组患者临床疗效、血压(收缩压、舒张压)以及心功能指标(左室射血分数、左室收缩末期容积、心排血量、心率)、6 min步行距离。结果观察组患者的治疗总有效率91.3%(42/46)高于对照组的76.1%(35/46),差异具有统计学意义(P<0.05)。治疗前,两组患者的左室射血分数、左室收缩末期容积、心排血量、心率、收缩压、舒张压水平比较,差异无统计学意义(P>0.05);治疗后,观察组患者左室射血分数、心排血量均高于对照组,左室收缩末期容积、心率、收缩压、舒张压水平均低于对照组,差异具有统计学意义(P<0.05)。观察组患者6 min步行距离为(366.57±45.68)m,长于对照组的(310.65±41.68)m,差异具有统计学意义(P<0.05)。结论采用曲美他嗪联合瑞舒伐他汀治疗缺血性心肌病心力衰竭,可改善患者的心功能,提升临床治疗疗效,有助于患者恢复健康,早日出院,具有可推广价值。

Objective To analyze the efficacy of trimetazidine combined with rosuvastatin in the treatment of heart failure in ischemic cardiomyopathy.Methods A total of 92 patients with ischemic cardiomyopathy and heart failure as the research subjects were divided into the control group and the observation group by computer system,with 46 cases in each group.The control group was treated with rosuvastatin,and the observation group was treated with trimetazidine and rosuvastatin.Both groups were compared in term of clinical efficacy,blood pressure(systolic blood pressure,diastolic blood pressure)and cardiac function indexes(left ventricular ejection fraction,left ventricular end-systolic volume,cardiac output,heart rate),and 6-min walking distance.Results The total effective rate of treatment 91.3%(42/46)in the observation group was higher than 76.1%(35/46)in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in left ventricular ejection fraction,left ventricular end-systolic volume,cardiac output,heart rate,systolic blood pressure,and diastolic blood pressure levels between the two groups(P>0.05).After treatment,the left ventricular ejection fraction and cardiac output of the observation group were higher than those of the control group,and the left ventricular end-systolic volume,heart rate,systolic blood pressure,and diastolic blood pressure levels were lower than those of the control group.All the differences were statistically significant(P<0.05).The 6-min walking distance in the observation group was(366.57±45.68)m,which was longer than(310.65±41.68)m in the control group,and the difference was statistically significant(P<0.05).Conclusion The combination of trimetazidine and rosuvastatin in the treatment of heart failure and ischemic cardiomyopathy can improve the heart function and clinical efficacy of patients,and help to recover health and discharge early,which contains the value of promotion.